Drug inducing myocarditis

PreclinicalSmall molecule

GGroupe Hospitalier Pitie-Salpetriere

Drug inducing myocarditis is one of 69 small molecule programs targeting Toxicity. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ToxicityActive, not recruiting

MyocarditisActive, not recruiting

Antiphospholipid SyndromeActive, not recruiting

ToxicityPreclinical

Active, not recruiting

MyocarditisPreclinical

Active, not recruiting

Antiphospholipid SyndromePreclinical

Active, not recruiting

Competition

Competitive Landscape

223 competitors in Toxicity

#DrugCompanyPhaseTrials

Cytotec

Pfizer

Phase 3

1 2

Coly-Mycin M

PParkedale

Phase 3

2 3

Mucosta

Otsuka

Phase 3

1 4

Sodium-Selenite

SStanford University

Phase 3

1 5

Cysteine Hydrochloride

Novartis

Preclinical

3 6

Dypirone

UUniversity of Sao Paulo General Hospital

Phase 3

1 7

Tenofovir/emtricitabine/rilpivirine

MMahidol University

Phase 3

1 8

Imfinzi

AstraZeneca

Preclinical

2 9

Cellcept

Novartis

Preclinical

2 10

Afinitor

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Toxicity1 trial

Monitoring the HeMAtological TOXicity of Drugs (HeMATOX)

Completed·GGroupe Hospitalier Pitie-Salpetriere··NCT03828942·1,000 enrolled

Antiphospholipid Syndrome1 trial

Monitoring the Antiphospholipid Syndrome:TOXicity of Drugs (APSTOX)

Completed·GGroupe Hospitalier Pitie-Salpetriere··NCT03994302·2,700 enrolled

Myocarditis1 trial

Monitoring Drug-induced Myocarditis (CardiTOX)

Completed·GGroupe Hospitalier Pitie-Salpetriere··NCT03855982·6,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Drug inducing myocarditis. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Drug inducing myocarditis compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Drug inducing myocarditis. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Groupe Hospitalier Pitie-Salpetriere company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GGroupe Hospitalier Pitie-Salpetriere

Drug inducing myocarditis

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Toxicity1 trial

Antiphospholipid Syndrome1 trial

Myocarditis1 trial

References

Drug Info

Quick Facts

Related News